Frank Leonard's most recent trade in NovoCure Ltd was a trade of 150,000 shares done . Disclosure was reported to the exchange on March 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NovoCure Ltd | Mr. Frank Leonard | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2026 | 150,000 | 499,400 (0%) | 0% | 0 | - | |
| NovoCure Ltd | Mr. Frank Leonard | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.31 per share. | 03 Mar 2026 | 5,607 | 493,793 (0%) | 0% | 13.3 | 74,603 | - |
| NovoCure Ltd | Mr. Frank Leonard | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2026 | 18,621 | 356,632 (0%) | 0% | 0 | - | |
| NovoCure Ltd | Mr. Frank Leonard | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.66 per share. | 27 Feb 2026 | 9,734 | 338,011 (0%) | 0% | 13.7 | 133,003 | - |
| NovoCure Ltd | Mr. Frank Leonard | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.49 per share. | 27 Feb 2026 | 7,232 | 349,400 (0%) | 0% | 13.5 | 97,581 | - |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.81 per share. | 01 Nov 2025 | 966 | 347,745 (0%) | 0% | 12.8 | 12,374 | - |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Grant, award, or other acquisition of securities at price $ 15.13 per share. | 30 Jun 2025 | 833 | 348,711 (0%) | 0% | 15.1 | 12,603 | - |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 179,426 | 347,878 (0%) | 0% | 0 | - | |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Sale of securities on an exchange or to another person at price $ 17.22 per share. | 02 Jun 2025 | 21,717 | 176,931 (0%) | 0% | 17.2 | 373,958 | - |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Sale of securities on an exchange or to another person at price $ 17.99 per share. | 02 Jun 2025 | 6,600 | 170,331 (0%) | 0% | 18.0 | 118,733 | - |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Sale of securities on an exchange or to another person at price $ 19.01 per share. | 02 Jun 2025 | 1,879 | 168,452 (0%) | 0% | 19.0 | 35,722 | - |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Grant, award, or other acquisition of securities at price $ 18.19 per share. | 04 Mar 2025 | 54,975 | 198,648 (0%) | 0% | 18.2 | 999,995 | - |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Sale of securities on an exchange or to another person at price $ 18.54 per share. | 03 Mar 2025 | 2,527 | 143,673 (0%) | 0% | 18.5 | 46,841 | - |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Sale of securities on an exchange or to another person at price $ 19.92 per share. | 27 Feb 2025 | 10,277 | 150,959 (0%) | 0% | 19.9 | 204,737 | - |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Sale of securities on an exchange or to another person at price $ 18.28 per share. | 27 Feb 2025 | 2,770 | 146,200 (0%) | 0% | 18.3 | 50,648 | - |
| NovoCure Ltd | Mr. Frank Leonard | EVP, Pres., Novocure Oncology | Sale of securities on an exchange or to another person at price $ 20.55 per share. | 27 Feb 2025 | 1,989 | 148,970 (0%) | 0% | 20.5 | 40,872 | - |
| NovoCure Ltd | Mr. Frank Leonard | President, CNS Cancers US | 01 Nov 2022 | 11,609 | 11,609 | - | - | Options to Buy Ordinary Shares | ||
| NovoCure Ltd | Mr. Frank Leonard | President, CNS Cancers US | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 6,830 | 50,456 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Mr. Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 76.01 per share. | 13 Oct 2022 | 6,754 | 43,626 (0%) | 0% | 76.0 | 513,372 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 84.37 per share. | 06 Oct 2022 | 6,754 | 50,380 (0%) | 0% | 84.4 | 569,835 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 77.35 per share. | 29 Sep 2022 | 6,754 | 57,134 (0%) | 0% | 77.4 | 522,422 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 77.00 per share. | 22 Sep 2022 | 6,754 | 63,888 (0%) | 0% | 77 | 520,058 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 87.31 per share. | 15 Sep 2022 | 6,754 | 76,159 (0%) | 0% | 87.3 | 589,692 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 15 Sep 2022 | 5,517 | 82,913 (0%) | 0% | 7.2 | 39,447 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | 15 Sep 2022 | 5,517 | 5,517 | - | - | Options to Buy Ordinary Shares | ||
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 15 Sep 2022 | 5,517 | 70,642 (0%) | 0% | 90 | 496,530 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 88.00 per share. | 09 Sep 2022 | 1,863 | 84,150 (0%) | 0% | 88 | 163,944 | - |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 81.48 per share. | 08 Sep 2022 | 6,754 | 77,396 (0%) | 0% | 81.5 | 550,316 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.57 per share. | 06 Sep 2022 | 1,384 | 86,013 (0%) | 0% | 78.6 | 108,741 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.08 per share. | 01 Sep 2022 | 2,955 | 96,277 (0%) | 0% | 78.1 | 230,741 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 77.92 per share. | 01 Sep 2022 | 2,720 | 90,155 (0%) | 0% | 77.9 | 211,934 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 77.00 per share. | 01 Sep 2022 | 1,914 | 99,232 (0%) | 0% | 77.0 | 147,382 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 76.96 per share. | 01 Sep 2022 | 1,750 | 92,875 (0%) | 0% | 77.0 | 134,677 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.93 per share. | 01 Sep 2022 | 1,200 | 94,625 (0%) | 0% | 75.9 | 91,114 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.68 per share. | 01 Sep 2022 | 1,088 | 89,067 (0%) | 0% | 78.7 | 85,602 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.94 per share. | 01 Sep 2022 | 1,047 | 101,146 (0%) | 0% | 75.9 | 79,504 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 79.04 per share. | 01 Sep 2022 | 584 | 87,397 (0%) | 0% | 79.0 | 46,158 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.66 per share. | 01 Sep 2022 | 452 | 95,825 (0%) | 0% | 78.7 | 35,556 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.14 per share. | 01 Sep 2022 | 438 | 88,029 (0%) | 0% | 78.1 | 34,225 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 77.06 per share. | 01 Sep 2022 | 360 | 88,467 (0%) | 0% | 77.1 | 27,742 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.88 per share. | 01 Sep 2022 | 240 | 88,827 (0%) | 0% | 75.9 | 18,210 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.96 per share. | 01 Sep 2022 | 48 | 87,981 (0%) | 0% | 79.0 | 3,790 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 69.66 per share. | 02 Aug 2022 | 414 | 102,193 (0%) | 0% | 69.7 | 28,839 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 59.07 per share. | 05 Jul 2022 | 312 | 102,607 (0%) | 0% | 59.1 | 18,431 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 70.10 per share. | 08 Mar 2022 | 744 | 102,295 (0%) | 0% | 70.1 | 52,154 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | 03 Mar 2022 | 30,422 | 30,422 | - | - | Options to Buy Ordinary Shares | ||
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 17,371 | 104,524 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | 03 Mar 2022 | 4,933 | 4,933 | - | - | Options to Buy Ordinary Shares | ||
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 74.50 per share. | 03 Mar 2022 | 930 | 103,594 (0%) | 0% | 74.5 | 69,283 | Ordinary Shares |
| NovoCure Ltd | Mr. Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 70.41 per share. | 03 Mar 2022 | 555 | 103,039 (0%) | 0% | 70.4 | 39,076 | Ordinary Shares |